Can a diabetes drug shield the heart before failure strikes?
NCT ID NCT06507657
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether empagliflozin, a drug originally for diabetes, can improve left atrial function in 80 adults over 60 with hypertension and obesity who are at risk for heart failure. Participants take either a 10 mg empagliflozin tablet or a placebo daily for 9 months. The goal is to see if the drug helps the heart's upper chambers work better, potentially preventing future heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin
What this could lead to
If it works, this could point toward a way to prevent heart failure in people with high blood pressure and obesity.
What could go wrong
This is a very early, small pilot study with only 80 participants. It may not show clear benefits, and empagliflozin can cause side effects like dehydration or urinary infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55414, United States
Contact Email: •••••@•••••